FDA advisors back approval of mRNA flu shot

An FDA advisory committee voted unanimously on June 18 to recommend that a messenger RNA-based influenza vaccine at the center of a recent change of heart by the FDA be approved for older adults.In two 9-0 votes, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) declared that the benefits of mRNA-1010 (mFlusiva, Moderna) outweigh the risks for adults aged 50